CN104873491A - Application of schisandrin b and schizandrin c in preparation of anti-hepatic fibrosis drug - Google Patents
Application of schisandrin b and schizandrin c in preparation of anti-hepatic fibrosis drug Download PDFInfo
- Publication number
- CN104873491A CN104873491A CN201510257521.XA CN201510257521A CN104873491A CN 104873491 A CN104873491 A CN 104873491A CN 201510257521 A CN201510257521 A CN 201510257521A CN 104873491 A CN104873491 A CN 104873491A
- Authority
- CN
- China
- Prior art keywords
- schisandrin
- hepatic fibrosis
- schizandrin
- group
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to the technical field of medicines; the main characteristic component of schisandra chinensis as the traditional Chinese medicine is a lignan component; the lignan component comprises schisandrin a, schisandrin b, schisandrin c and the like; and modern pharmacological tests prove that the lignan component has multiple pharmacological activities for protecting liver, resisting oxidization and the like. The invention provides novel medical application of schisandrin b and schizandrin c, and in particular provides application of schisandrin b and schizandrin c in preparation of an anti-hepatic fibrosis drug. Pharmacodynamics researches show that schisandrin b and schizandrin c can be used for obviously reducing the concentration of ALT (Alanine Aminotransferase) and AST (Aspartate Transaminase) in rat serum of a hepatic fibrosis model induced by common bile duct ligation and CCL4 and improving hepatic fibrosis symptoms, and have good anti-hepatic fibrosis activity; and therefore, schisandrin b and schizandrin c can be used for preparing anti-hepatic fibrosis drugs or health-care foods.
Description
Technical field:
The present invention relates to medical art, be specifically related to schisandrin B, schisandrin C is preparing the application in anti-hepatic fibrosis medicines or health food.
Background technology:
Liver cirrhosis is one of commonly encountered diseases of serious harm human health, and the incidence rate of current China still remains on higher level.The pathologic basis of liver cirrhosis is hepatic fibrosis, the latter is the liver injury that causes of various damage liver factor (as the damage of viral hepatitis, alcoholic liver disease, some metabolic disease, medicine and chemical toxicant and hepatic parasitosis etc.) and inflammation, so cause chronic hepatopathy to develop into liver cirrhosis must through pathological process.Hepatic fibrosis is the common pathological characters of most of chronic hepatopathy, is also chronic hepatitis, the liver cirrhosis important intermediate link that further develops, worsen.Modern study shows: have the patient of 20% to 40% finally can develop into liver cirrhosis in patients with liver fibrosis, even hepatocarcinoma.Therefore the generation of hepatic fibrosis is effectively blocked, to treatment hepatic disease important in inhibiting.“
Be instruct the fibrosis research carried out in recent years with Chinese medical theory, its toxic and side effects possessed is little, the feature that therapeutic effect is good, has been widely used in experiment and clinical research.Chinese medicine Schisandra chinensis begins to be loaded in Shennong's Herbal, and is listed in top grade.The primary efficacy of Fructus Schisandrae Chinensis is astringed the lung, and nourishing kidney is promoted the production of body fluid, and receives antiperspirant, arresting seminal emission.Modern pharmacological research shows: Fructus Schisandrae Chinensis has antiinflammatory, protection and strengthens the effect such as heart body, expansion blood vessel.Main in Fructus Schisandrae Chinensis containing Fructus Schisandrae Polysaccharide, volatile oil and lignan component, wherein lignin composition has hepatoprotective effect, but wherein which chemical composition plays effect of anti hepatic fibrosis and has no pertinent literature report.
Summary of the invention:
The object of the invention is to which chemical composition in deep parsing Fructus Schisandrae Chinensis and there is effect of anti hepatic fibrosis, another object of the present invention is to the medical usage providing schisandrin B, schisandrin C new.
The present inventor studies and finds schisandrin B, schisandrin C has significant effect of anti hepatic fibrosis.The present invention proves through zoopery: adopt deoxyschizandrin, schisandrin B, schisandrin C constituents effect of anti hepatic fibrosis research experiment, and discovery schisandrin B, schisandrin C can reduce the index such as HA, LN, collagen type v in rat blood serum; Adopt CCl
4the Rat Liver Fibrosis Model experiment of induction, discovery schisandrin B, schisandrin C significantly can reduce the concentration of ALT, AST in rat blood serum, improve hepatic tissue pathology symptom, reduce the content of rat liver type III collagen, there is good effect of anti hepatic fibrosis, therefore schisandrin B, schisandrin C play therapeutical effect to hepatic fibrosis, and deoxyschizandrin does not have remarkable therapeutical effect to fibrosis.
The invention provides schisandrin B, schisandrin C is preparing the application in anti-hepatic fibrosis medicines or health food.
Anti-hepatic fibrosis of the present invention, refers to prevention or treatment hepatic fibrosis.
The pharmaceutical composition that medicine of the present invention is made up of active constituents of medicine schisandrin B, schisandrin C and pharmaceutically acceptable adjuvant.
Pharmaceutical composition of the present invention can adopt the method for medical domain routine, using schisandrin B, schisandrin C as active component, make pharmaceutical preparation with pharmaceutically acceptable adjuvant, in described pharmaceutical preparation, the weight content of active component is 0.1% ~ 99.9%.
The present invention not only specify that in Fructus Schisandrae Chinensis, which chemical composition has effect of anti hepatic fibrosis, and provides new means for hepatic fibrosis clinical treatment.
Accompanying drawing illustrates:
HE colored graph after Fig. 1: CCL4 modeling administration, wherein A is model group, and B is deoxyschizandrin group, and C is schisandrin B group, and D is schisandrin C group;
S-red colored graph after Fig. 2: CCL4 modeling administration, wherein A is model group, and B is deoxyschizandrin group, and C is schisandrin B group, and D is schisandrin C group.
Detailed description of the invention:
Below in conjunction with accompanying drawing and concrete enforcement, the invention will be further described.Should be understood that following enforcement only for illustration of the present invention but not for limiting scope of the present invention.
Embodiment 1: deoxyschizandrin, schisandrin B, schisandrin C are to the therapeutical effect of common bile duct ligation Liver Fibrosis Model rat
Common bile duct ligation hepatic fibrosis experiment (Xu Shuyun, Bian Rulian, Chen Xiu. pharmacological experimental methodology, the 3rd edition [M]. Beijing: People's Health Publisher, 2002:807).Concrete grammar is as follows:
SD rat, male and female half and half, in 6 ~ 8 week age, body weight 200 ± 10g, Second Military Medical University, PLA's Experimental Animal Center provides.
Receptacle temperature 18-22 DEG C, relative humidity 60%-75%, artificial mixed fodder is fed.
Random packet, often organizes 10 rats: blank group, model group, deoxyschizandrin group (25mg/kgd), deoxyschizandrin group (50mg/kgd), deoxyschizandrin group (75mg/kgd), schisandrin B group (25mg/kgd), schisandrin B group (50mg/kgd), schisandrin B group (75mg/kgd), schisandrin C group (25mg/kgd), schisandrin C group (50mg/kgd), schisandrin C group (75mg/kgd).Sham operated rats is abdominal incision only, is separated common bile duct, does not do common bile duct ligation, then sew up.Common bile duct ligation group three days after surgery, administration group carries out administration, the normal saline of blank group gavage equivalent.
After administration 3w, put to death mouse in the 25th day.Hepatic portal vein gets blood, after static, and centrifuging and taking serum.Detect HA (hyaluronidase), LN albumen, type III collagenous amino-tenminal, collagen type v, total protein, total bilirubin.
The results are shown in Table 1.
From table 1, indices in model group is all significantly higher than sham operated rats, proof modeling success, relative to sham operated rats and model group, dosage is that the schisandrin B of 25mg/mL and the biochemical detection indexes of schisandrin C group raise, but along with the increasing of dosage, schisandrin B, schisandrin C group significantly can reduce the indexs such as HA (hyaluronidase), LN albumen, type III collagenous amino-tenminal, collagen type v, total protein, total bilirubin, but these indexs of deoxyschizandrin group do not have reducing effect.
Experimental result shows, schisandrin B, schisandrin C have inhibitory action to common bile duct ligation hepatic fibrosis, and deoxyschizandrin does not have anti-fibrosis effect significantly.
Embodiment 2: deoxyschizandrin, schisandrin B, schisandrin C are to CCL
4the rat therapeutical effect of the Liver Fibrosis Model of induction
CCL
4the Liver Fibrosis Model of inducing is tested (Xu Shuyun, Bian Rulian, Chen Xiu. pharmacological experimental methodology, the 3rd edition [M]. Beijing: People's Health Publisher, 2002:807).Concrete grammar is as follows:
SD rat, male and female half and half, in 6 ~ 8 week age, body weight 200 ± 10g, Second Military Medical University, PLA's Experimental Animal Center provides.
Receptacle temperature 18-22 DEG C, relative humidity 60%-75%, artificial mixed fodder is fed.
Random packet, often organize 10 rats: blank group, model group, deoxyschizandrin group (25mg/kgd), deoxyschizandrin group (50mg/kgd), deoxyschizandrin group (75mg/kgd), schisandrin B group (25mg/kgd), schisandrin B group (50mg/kgd), schisandrin B group (75mg/kgd), schisandrin C group (25mg/kgd), schisandrin C group (50mg/kgd), schisandrin C group (75mg/kgd).To the CCL of each group of rat according to the injected dose lumbar injection 35% of 2ml/kg
4peanut oil solution, 2 times weekly, injects 6w altogether, the formation of induction Liver Fibrosis Model.Administration group gastric infusion from the 7th week, the normal saline of model group and blank group gavage equivalent.Administration three weeks, put to death mouse after three weeks altogether.Getting same area hepatic tissue neutral formalin to fix, for doing paraffin section, carrying out HE and S-red dyeing, all the other hepatic tissue liquid nitrogen cryopreservations.Hepatic portal vein gets blood, after static, and centrifuging and taking serum.Detect HA (hyaluronidase), Piii, TBIl index.The results are shown in Table 2, Fig. 1, Fig. 2.
Table 2:CCL
4administration biochemical detection indexes after modeling
From table 2, indices in model group is all significantly higher than sham operated rats, proof modeling success, along with schisandrin B, the increase of schisandrin C dosage, TBIl value after modeling, HA (hyaluronidase) value significantly reduces, but these indexs of deoxyschizandrin group do not reduce, and composition graphs 1, 2 is visible, schisandrin B, the collage synthesis amount of schisandrin C group comparatively model group obviously reduces, the collage synthesis amount of deoxyschizandrin group does not reduce, schisandrin B is described, schisandrin C has inhibitory action to hepatic fibrosis, deoxyschizandrin does not have anti-fibrosis effect significantly.
Above-mentioned experimental result shows, schisandrin B, schisandrin C significantly can reduce the concentration of ALT, AST in rat blood serum, improve hepatic tissue pathology symptom, reduce the content of rat liver type III collagen, and deoxyschizandrin does not have the effect of fibrosis.Schisandrin B is described, schisandrin C effectively suppresses hepatic fibrosis that there is the novelty teabag that treatment hepatic fibrosis is relevant.
Below the preferred embodiment of the invention is illustrated, but the invention is not limited to described embodiment, those of ordinary skill in the art also can make all equivalent modification or replacement under the prerequisite without prejudice to the invention spirit, and these equivalent modification or replacement are all included in the application's claim limited range.
Experimental result shows, deoxyschizandrin does not have therapeutical effect to anti-hepatic fibrosis, and schisandrin B, schisandrin C have the novelty teabag for the treatment of hepatic fibrosis.
Below the preferred embodiment of the invention is illustrated, but the invention is not limited to described embodiment, those of ordinary skill in the art also can make all equivalent modification or replacement under the prerequisite without prejudice to the invention spirit, and these equivalent modification or replacement are all included in the application's claim limited range.
Claims (3)
1. schisandrin B, schisandrin C are preparing the application in anti-hepatic fibrosis medicines or health food.
2. schisandrin B according to claim 1 and 2, schisandrin C are preparing the application in anti-hepatic fibrosis medicines or health food, it is characterized in that, the pharmaceutical composition that described medicine is made up of active constituents of medicine schisandrin B, schisandrin C and pharmaceutically acceptable adjuvant.
3. schisandrin B according to claim 1 and 2, schisandrin C are preparing the application in anti-hepatic fibrosis medicines or health food, it is characterized in that, described pharmaceutical composition can adopt the method for medical domain routine, using schisandrin B, schisandrin C as active component, pharmaceutical preparation is made with pharmaceutically acceptable adjuvant, in described pharmaceutical preparation, the weight content of active component is 0.1% ~ 99.9%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510257521.XA CN104873491B (en) | 2015-05-19 | 2015-05-19 | The application of deoxyschizandrin, schisandrin C in anti-hepatic fibrosis medicines are prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510257521.XA CN104873491B (en) | 2015-05-19 | 2015-05-19 | The application of deoxyschizandrin, schisandrin C in anti-hepatic fibrosis medicines are prepared |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104873491A true CN104873491A (en) | 2015-09-02 |
| CN104873491B CN104873491B (en) | 2017-09-12 |
Family
ID=53941348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510257521.XA Active CN104873491B (en) | 2015-05-19 | 2015-05-19 | The application of deoxyschizandrin, schisandrin C in anti-hepatic fibrosis medicines are prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104873491B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109157534A (en) * | 2018-08-09 | 2019-01-08 | 杜彬 | Purposes of the deoxyschizandrin in preparation prevention or treatment renal fibrosis drug |
| CN110585193A (en) * | 2017-09-13 | 2019-12-20 | 北京理工大学 | Application of diaryl butyrolactone lignan compound in preparation of anti-hepatic fibrosis medicine |
| CN112107575A (en) * | 2020-08-10 | 2020-12-22 | 中国人民解放军总医院第五医学中心 | Lignan compound combined with furocoumarin compound for treating hepatic fibrosis |
| CN113274385A (en) * | 2021-07-13 | 2021-08-20 | 中国人民解放军总医院第五医学中心 | Pharmaceutical composition for treating chronic liver injury and application thereof |
| CN114394890A (en) * | 2022-01-19 | 2022-04-26 | 上海市第一人民医院 | Schizandrol A metabolite and application thereof in preparation of medicine for resisting idiopathic pulmonary fibrosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103860544A (en) * | 2012-12-10 | 2014-06-18 | 中国人民解放军军事医学科学院毒物药物研究所 | Use of schisandrin B in anti-liver fibrosis |
| CN103860565A (en) * | 2012-12-10 | 2014-06-18 | 中国人民解放军军事医学科学院毒物药物研究所 | Medicinal composition for treating diabetes hepatic fibrosis |
-
2015
- 2015-05-19 CN CN201510257521.XA patent/CN104873491B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103860544A (en) * | 2012-12-10 | 2014-06-18 | 中国人民解放军军事医学科学院毒物药物研究所 | Use of schisandrin B in anti-liver fibrosis |
| CN103860565A (en) * | 2012-12-10 | 2014-06-18 | 中国人民解放军军事医学科学院毒物药物研究所 | Medicinal composition for treating diabetes hepatic fibrosis |
Non-Patent Citations (3)
| Title |
|---|
| TAOYANG等: "Comparative pharmacokinetics and tissue distribution profiles of lignan components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe", 《JOURNAL OFETHNOPHARMACOLOGY》 * |
| 余凌虹等: "五味子联苯环辛烯类木脂素成分的结构与药理活性关系和药物创新", 《化学进展》 * |
| 张子敬: "《形态学实验教程——病理学分册》", 30 August 2014 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110585193A (en) * | 2017-09-13 | 2019-12-20 | 北京理工大学 | Application of diaryl butyrolactone lignan compound in preparation of anti-hepatic fibrosis medicine |
| CN110585193B (en) * | 2017-09-13 | 2022-08-02 | 北京理工大学 | Application of diaryl butyrolactone lignan compound in preparation of anti-hepatic fibrosis medicine |
| CN109157534A (en) * | 2018-08-09 | 2019-01-08 | 杜彬 | Purposes of the deoxyschizandrin in preparation prevention or treatment renal fibrosis drug |
| CN112107575A (en) * | 2020-08-10 | 2020-12-22 | 中国人民解放军总医院第五医学中心 | Lignan compound combined with furocoumarin compound for treating hepatic fibrosis |
| CN113274385A (en) * | 2021-07-13 | 2021-08-20 | 中国人民解放军总医院第五医学中心 | Pharmaceutical composition for treating chronic liver injury and application thereof |
| CN114394890A (en) * | 2022-01-19 | 2022-04-26 | 上海市第一人民医院 | Schizandrol A metabolite and application thereof in preparation of medicine for resisting idiopathic pulmonary fibrosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104873491B (en) | 2017-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104873491A (en) | Application of schisandrin b and schizandrin c in preparation of anti-hepatic fibrosis drug | |
| US10959963B2 (en) | Method for the treatment of fatty liver disease | |
| WO2009043176A1 (en) | Herbal compositions and methods for treating hepatic disorders | |
| Ita et al. | Acetaminophen induced hepatic toxicity: protective role of Ageratum conyzoides | |
| CN109045035A (en) | Application of 7- (2,2- dimethyl -3- crotonoyl the amido)-octahydro benzene quinoline acetic acid esters in preparation treatment liver disease drug | |
| CN104887813A (en) | Schisandra chinensis alcohol extract and application thereof to prepare anti-hepatic fibrosis medicine | |
| CN104523925B (en) | Traditional Chinese medicinal composition and its application in defecation promotion | |
| CN103800352A (en) | Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof | |
| CN102406665A (en) | Application of physically modified cobra venom in preparing medicine for treating arthritis | |
| CN114948937A (en) | Application of schisandrin in preparation of medicine for treating hepatotoxicity of regorafenib | |
| CN108524828B (en) | Traditional Chinese medicine composition for treating ascites due to cirrhosis as well as preparation method and application thereof | |
| CN108236607A (en) | Application of the talan dimer in the drug for preparing treatment liver related disease | |
| US8206760B2 (en) | Composition for inhibition of transplant rejection containing the cordyceps mycellia extract as an active ingredient | |
| CN105535866A (en) | Medicine for treating hyperlipidemia and preparation method thereof | |
| CN103948780B (en) | A kind of medicine and capsule for constipation | |
| CN103751174A (en) | Application of schisandra chinensis monomer compound in preparation of drugs for prevention and treatment of hepatotoxicity caused by acetaminophen | |
| Baniasad et al. | Hepatotoxicity due to mushroom poisoning: A case report | |
| CN107213254A (en) | Purposes of the Compound Xueshuantong preparation in the treatment disease mediated medicines of PAF are prepared | |
| CN113577076B (en) | Application of gelsemine in preparation of medicine for treating acute lung injury | |
| CN109106917B (en) | Application of traditional Chinese medicine composition in preparation of acute liver injury medicine | |
| CN104510761A (en) | Ovateleaf Holly Bark extract product having hepatic injury prevention effect, and application thereof | |
| CN106983753A (en) | White adipose tissue brown sample becomes stimulant and prepares the application for resisting antiobesity agents | |
| CN101327217A (en) | Use of indinavir sulfate and chloroquine in preparing compound antimalarial medicament | |
| Cha et al. | A study on single dose toxicity of Mecasin pharmacopuncture injection in muscle | |
| CN113679751A (en) | Application of extract in preparation of medicines for reducing morphine-induced hepatotoxicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |